Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin - PubMed
4 hours ago
- #IVIG
- #myasthenia-gravis
- #efgartigimod
- Efgartigimod (EFG) was compared with intravenous immunoglobulin (IVIG) in patients with generalized myasthenia gravis (MG).
- No significant differences were found between EFG and IVIG in achieving minimal manifestations (MM) or reducing prednisolone doses.
- Patients switching to EFG experienced fewer hospitalizations and improved quality of life (QOL) scores.
- EFG was favored for supporting family roles, work participation, and social activities.
- Despite a small sample size, EFG showed therapeutic benefits over IVIG, reducing hospitalization rates and enhancing QOL.